Butrynski et al. reported a case of IMT in a patient with the RANBP2-ALK fusion gene who was treated with the ALK inhibitor crizotinib after surgical tumor resection, in which 19 months have passed without evidence of recurrence [20]. This evidence concerns the gene ALK and inflammatory myofibroblastic tumor.